Last 4,544 GBp
Change Today +43.50 / 0.97%
Volume 3.0M
As of 12:35 PM 10/31/14 All times are local (Market data is delayed by at least 15 minutes).

astrazeneca plc (AZN) Snapshot

4,550 GBp
Previous Close
4,500 GBp
Day High
4,600 GBp
Day Low
4,518 GBp
52 Week High
05/2/14 - 4,845 GBp
52 Week Low
11/8/13 - 3,248 GBp
Market Cap
Average Volume 10 Days
1.60 GBp
Shares Outstanding
2.98 GBp
Dividend Yield
Current Stock Chart for ASTRAZENECA PLC (AZN)

astrazeneca plc (AZN) Details

AstraZeneca PLC is engaged in the discovery, development, and commercialization of medicines for cardiovascular and metabolic disease; oncology; respiratory, inflammation, and autoimmunity; and infection, neuroscience, and gastrointestinal disease areas worldwide. Its principal products include Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL for control of hypertension and for use in heart failure and angina; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; and Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders. The company's principal products also comprise Pulmicort for treating asthma and chronic obstructive pulmonary disease (COPD); Symbicort for maintenance treatment of asthma and COPD; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients. In addition, it has 99 pipeline projects, which include 85 in clinical development and 14 either approved, launched, or filed. The company markets its products to primary care and specialist doctors through distributors or local representative offices. AstraZeneca PLC has collaboration agreements with Amgen, Inc.; FibroGen, Inc.; Roche Holding AG; Qiagen N.V.; and Illumina, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in London, the United Kingdom.

51,500 Employees
Last Reported Date: 03/20/14
Founded in 1992

astrazeneca plc (AZN) Top Compensated Officers

Chief Executive Officer, Executive Director a...
Total Annual Compensation: 3.0M GBP
Chief Financial Officer and Executive Directo...
Total Annual Compensation: 259.0K GBP
Compensation as of Fiscal Year 2013.

astrazeneca plc (AZN) Key Developments

AstraZeneca Receives Approval from US Food and Drug Administration for Once-Daily XIGDUO XR Tablets

AstraZeneca announced that the US Food and Drug Administration has approved once-daily XIGDUO XR (dapagliflozin and metformin hydrochloride extended-release) for the treatment of adults with type 2 diabetes. XIGDUO XR combines two anti-hyperglycaemic agents with complementary mechanisms of action, dapagliflozin (trade name in the US, FARXIGATM), an inhibitor of sodium-glucose cotransporter 2 (SGLT2), and metformin hydrochloride (HCl) extended-release, a biguanide, in a once-daily oral tablet. SGLT2 inhibitors are a relatively new class of medicines that remove glucose from the body via the kidneys. XIGDUO XR is the first and only once-daily combination tablet of an SGLT2 inhibitor and metformin HCl extended-release to be approved in the United States. XIGDUO XR is indicated as an adjunct therapy to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both dapagliflozin and metformin is appropriate. XIGDUO XR is already approved in Australia for the treatment of adults with type 2 diabetes, along with diet and exercise. XIGDUO (dapagliflozin and metformin hydrochloride), which uses an immediate-release form of metformin, is approved in the European Union.

AstraZeneca Receives Positive CHMP Opinion on Olaparib

AstraZeneca announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the marketing authorisation of Lynparza™ (olaparib) as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed BRCA-mutated high grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response to platinum-based chemotherapy. Olaparib is a poly ADP-ribose polymerase (PARP) inhibitor that exploits tumour DNA repair pathway deficiencies to preferentially kill cancer cells. The positive CHMP opinion was based on the results from Study 191, a Phase II clinical trial that evaluated the efficacy and safety of olaparib compared to placebo in platinum sensitive relapsed high grade serous ovarian cancer patients. The study showed that olaparib maintenance therapy significantly prolonged progression free survival (PFS) compared with placebo in patients with BRCA-mutated ovarian cancer- median PFS 11.2 months vs. 4.3 months (PFS HR=0.18; 95% CI 0.10-0.31; p<0.0001). The most common adverse events associated with olaparib monotherapy to date were generally mild to moderate and included nausea, vomiting, fatigue and anaemia. The CHMP's positive opinion on olaparib will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union. The final decision will be applicable to all 28 European Union member countries plus Iceland, Norway and Liechtenstein. If approved, Lynparza will be the first PARP inhibitor available in these markets for the treatment of platinum sensitive relapsed BRCA-mutated high grade serous ovarian cancer.

The State of Texas Sues AstraZeneca over Payments for Seroquel

The state of Texas alleges that AstraZeneca provided misleading information about antipsychotic products in order to receive Medicare and Medicaid reimbursement. According to the lawsuit, AstraZeneca officials downplayed side effects and promoted both Seroquel and Seroquel XR for unapproved uses. Both drugs are atypical antipsychotic medications used to treat serious mental disorders such as schizophrenia and bipolar disorder. The lawsuit also alleges that AstraZeneca concealed the potent nature of those drugs and promoted the use of the drugs in the pediatric population and for treatment of depression. As a result, the state made payments to AstraZeneca that it otherwise would not have made. The complaint alleges violations of the Texas Medicaid Fraud Prevention Act.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AZN:LN 4,543.50 GBp +43.50

AZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $63.46 USD +2.28
Bristol-Myers Squibb Co $58.19 USD -0.79
Celgene Corp $107.09 USD +0.15
Eli Lilly & Co $66.33 USD -0.47
Novo Nordisk A/S kr268.70 DKK -2.70
View Industry Companies

Industry Analysis


Industry Average

Valuation AZN Industry Range
Price/Earnings 45.3x
Price/Sales 3.5x
Price/Book 4.2x
Price/Cash Flow 45.4x
TEV/Sales 3.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTRAZENECA PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at